Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

New Antigens Introduced For Use In Diagnostic Manufacturing And Research

By Binding Site, Inc. | July 31, 2018

Binding Site’s Immunologicals Group introduced highly purified Borrelia and Chikungunya Glycoprotein antigens for use in both in-vitro diagnostic (IVD) manufacturing and research applications. 

The availability of the antigens is expected to benefit the needs of IVD assay manufacturers; clinical, biopharmaceutical, and life science researchers; and other allied health professionals, as the antigens have been expressly designed for use as an integral component within solid phase ELISA-based immunoassay test procedures.

The antigens being introduced include Borrelia afzelii–Pko DbpA; Borrelia afzelii–Pko OspC; Chikungunya Glycoprotein–E2; Chikungunya Glycoprotein–E1; and Chikungunya Glycoprotein–E1 – A226V. 

All of the antigens are derived and sourced from infected cells, via culture, which are then treated by heat, detergent, chemical, or UV irradiation to inactivate the pathogenic components. All exhibit high purity levels as a result of either chromatography, cross flow ultra-filtration, ultra-centrifugation, or extraction processes and display the highest degrees of activity and specificity. 

In addition, the antigens demonstrate lot-to-lot consistency and feature a shelf life stability claim of 10 years from the date of manufacture. The available antigens are offered in a standard packaging formats of 1.0 mg fill vials, with larger, bulk configurations also available.

Binding Site’s Immunologicals Group serves the in-vitro diagnostic manufacturing and clinical/life-science research markets.

(Source and Image Credit: Binding Site, Inc.)


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-mole 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50